Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
dc.contributor.author | Everson, Gregory T. | en_US |
dc.contributor.author | Hoefs, John C. | en_US |
dc.contributor.author | Seeff, Leonard B. | en_US |
dc.contributor.author | Bonkovsky, Herbert L. | en_US |
dc.contributor.author | Naishadham, Deepa | en_US |
dc.contributor.author | Shiffman, Mitchell L. | en_US |
dc.contributor.author | Kahn, Jeffrey A. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Di Bisceglie, Adrian M. | en_US |
dc.contributor.author | Lee, William M. | en_US |
dc.contributor.author | Dienstag, Jules L. | en_US |
dc.contributor.author | Ghany, Marc G. | en_US |
dc.contributor.author | Morishima, Chihiro | en_US |
dc.date.accessioned | 2007-09-20T17:55:07Z | |
dc.date.available | 2008-01-03T16:21:36Z | en_US |
dc.date.issued | 2006-12 | en_US |
dc.identifier.citation | Everson, Gregory T.; Hoefs, John C.; Seeff, Leonard B.; Bonkovsky, Herbert L.; Naishadham, Deepa; Shiffman, Mitchell L.; Kahn, Jeffrey A.; Lok, Anna S. F.; Di Bisceglie, Adrian M.; Lee, William M.; Dienstag, Jules L.; Ghany, Marc G.; Morishima, Chihiro (2006). "Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial Potential conflict of interest: Dr. Everson is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Shiffman is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. He also advises for and received grants from Schering-Plough. He is a consultant and advises for Valeant. He also advises for Novartis. Dr. Hoefs is on the speakers' bureau of Roche. Dr. Bonkovsky is on the speaker's bureau of and received grants from Roche. He is on the speakers' bureau of Schering-Plough. Dr. Kahn is on the speakers' bureau of Gilead. He is a consultant and is on the speakers' bureau of Roche. Dr. Lok is a consultant for, advises, and received grants from Roche, GlaxoSmithKline, Gilead, Idenix, Innogenetics, and Bristol-Myers Squibb. She received grants from Schering-Plough and Valeant. She owns stock in, is a consultant, and advises for Andays. She is a consultant and advises for Pharmasset. Dr. Di Bisceglie is a consultant for and received grants from Roche. Dr. Lee received grants from Roche ." Hepatology 44(6): 1675-1684. <http://hdl.handle.net/2027.42/55880> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55880 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17133499&dopt=citation | en_US |
dc.description.abstract | In patients with chronic hepatitis C, advanced fibrosis and cirrhosis are associated with lower rates of sustained virologic response (SVR) to interferon (IFN)-based therapy. In this study, we assessed virologic response to retreatment with peginterferon alfa-2a and ribavirin (RBV), as a function of the baseline fibrosis score (Ishak staging) and platelet count, in 1,046 patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. All patients had failed prior treatment with IFN or peginterferon ± RBV and had Ishak fibrosis scores ≥ 3. Four groups of patients with increasingly severe liver disease were compared: (A) bridging fibrosis (Ishak 3 and 4) with platelet counts >125,000/mm 3 (n = 559); (B) bridging fibrosis with platelet counts ≤125,000/mm 3 (n = 96); (C) cirrhosis (Ishak 5 and 6) with platelet counts >125,000/mm 3 (n = 198); and (D) cirrhosis with platelet counts ≤125,000/mm 3 (n = 193). SVR rates were 23%, 17%, 10%, and 9% in groups A, B, C, and D, respectively ( P < .0001 for trend). Reduction in SVR as a function of increasingly severe disease was independent of age, percent African American, HCV genotype, HCV level, and type of prior therapy. Dose reduction lowered SVR frequencies, but to a lesser extent than disease severity. By logistic regression, cirrhosis ( P < .0001) was the major determinant that impaired virologic response, independent of dose reduction or platelet count. In conclusion , disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these “difficult-to-cure” patients. (H EPATOLOGY 2006;44:1675–1684.) | en_US |
dc.format.extent | 363213 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO ; fax: 303-372-8868 ; Professor of Medicine, Director of Hepatology, University of Colorado Health Sciences Center, 4200 East 9 th Avenue, B-154, Denver, CO 80262 | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, University of California—Irvine, Irvine, CA | en_US |
dc.contributor.affiliationother | Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT | en_US |
dc.contributor.affiliationother | New England Research Institutes, Watertown, MA | en_US |
dc.contributor.affiliationother | Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA | en_US |
dc.contributor.affiliationother | Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO | en_US |
dc.contributor.affiliationother | Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX | en_US |
dc.contributor.affiliationother | Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, MA | en_US |
dc.contributor.affiliationother | Liver Diseases Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD | en_US |
dc.contributor.affiliationother | Department of Laboratory Medicine, University of Washington, Seattle, WA | en_US |
dc.identifier.pmid | 17133499 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55880/1/21440_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/hep.21440 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.